Tags: Diabetes | diabetes | drug | effective | FDA | review

Diabetes Drug Effective, No Heart Risks: FDA Review

Diabetes Drug Effective, No Heart Risks: FDA Review
(Copyright DPC)

Monday, 16 October 2017 03:06 PM

Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday.

The review, posted on the FDA's website on Monday, comes two days ahead of a meeting of advisors to the agency who will discuss the drug, semaglutide, and recommend whether it should be approved.

The FDA typically follows the recommendations of its advisors.

"The review for efficacy supports the claim of using semaglutide for improving glycemic control in adults with type 2 diabetes," the review said. The reviewers found no additional cardiovascular risk associated with the drug.

There was an increase in the number of people who developed sight problems, the review said, but concluded there was "no reason to restrict semaglutide with respect to population or dosing schedule."

© 2020 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Diabetes
Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective, a preliminary review by the U.S. Food and Drug Administration concluded, sending the company's shares up 3.4 percent in premarket trading on Monday.The review, posted on the FDA's website on Monday,...
diabetes, drug, effective, FDA, review
142
2017-06-16
Monday, 16 October 2017 03:06 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved